INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
发明人:
PELUS, LOUIS M.,HOGGATT, JONATHAN,SINGH, PRATIBHA
申请号：
CA2742876
公开号：
CA2742876C
申请日:
2009.11.06
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
This disclosure is directed to the methods of enhancing hematopoietic stemcells (HSPC) and progenitor cell(HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compoundsthat reduce PGE2 biosynthesis or PGE2re-ceptor antagonists alone, or in combination with other hematopoieticmobilization agents such as AMD3100 and G-CSF,increas-es the circulation of available HSPCs. Compounds that reduce thecellular synthesis of PGE2 include non-steroidalanti-inflamma-tory compounds such as indomethacin. Treatment ex vivo of HSPCwith an effective amount of PGE2 or at least one of itsderiva-tives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPCengraftment. Similar methods may also be used toin-crease viral-mediated gene transduction efficacy into HSPC.
